{
    "pmcid": "8651051",
    "qa_pairs": {
        "What advantage do bispecific antibodies have over conventional monoclonal antibodies according to the study?": [
            "Ability to cross-link adjacent spike proteins",
            "Higher affinity for the ACE2 receptor",
            "Longer half-life in the bloodstream",
            "Reduced production costs"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein as described in the paper?": [
            "Facilitates viral entry into host cells by binding to the ACE2 receptor",
            "Acts as a decoy to evade the host immune system",
            "Serves as a structural component of the viral capsid",
            "Functions as an enzyme to replicate viral RNA"
        ],
        "What potential advantage do nanobodies have over traditional antibodies for therapeutic use as mentioned in the paper?": [
            "Smaller size and potential for inhalation delivery",
            "Higher specificity for the ACE2 receptor",
            "Greater resistance to all known mutations",
            "Ability to integrate into host DNA"
        ],
        "Which regions of the spike protein are targeted by the bispecific antibodies developed in the study?": [
            "Distinct epitopes on the spike protein",
            "Only the receptor-binding domain (RBD)",
            "Only the N-terminal domain (NTD)",
            "The S2 subunit exclusively"
        ],
        "Which specific region on the RBD is highlighted as a target for potent antibody binding in the study?": [
            "The ridge region",
            "The core region",
            "The loop region",
            "The base region"
        ]
    }
}